Precision medicine is an emerging approach to treatment and disease prevention that relies on linkages between very large datasets of health information shared amongst researchers and health professionals. While studies suggest broad support for data sharing with researchers at publicly funded institutions, there is reluctance to share health information with private industry for research and development. This study reports outcomes of a deliberative method of citizen engagement in Singapore that asked whether sharing precision medicine data with private industry would be permissible, and if so, under what circumstances.

Findings from this citizens’ jury suggest sharing with industry would be permissible under certain conditions that are set out in nine recommendations. Our results corroborate with prior international studies, which found conditional acceptance for data sharing with private industry, a public benefit requirement, specific reluctance to share with insurance companies and an emphasis on accountability and transparency to demonstrate trustworthiness. Opt-in consent did not dominate the deliberations as jurors were able to set it aside as an assumed prerequisite for participation in a precision medicine programme.